AVBP Strangle Strategy

AVBP (ArriVent BioPharma, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

AVBP (ArriVent BioPharma, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.35B, a beta of 1.52 versus the broader market, a 52-week range of 16.1-32.14, average daily share volume of 493K, a public-listing history dating back to 2024, approximately 52 full-time employees. These structural characteristics shape how AVBP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.52 indicates AVBP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on AVBP?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current AVBP snapshot

As of May 15, 2026, spot at $28.06, ATM IV 119.80%, IV rank 22.85%, expected move 34.35%. The strangle on AVBP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on AVBP specifically: AVBP IV at 119.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a AVBP strangle, with a market-implied 1-standard-deviation move of approximately 34.35% (roughly $9.64 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AVBP expiries trade a higher absolute premium for lower per-day decay. Position sizing on AVBP should anchor to the underlying notional of $28.06 per share and to the trader's directional view on AVBP stock.

AVBP strangle setup

The AVBP strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AVBP near $28.06, the first option leg uses a $29.46 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AVBP chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AVBP shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$29.46	N/A
Buy 1	Put	$26.66	N/A

AVBP strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

AVBP strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on AVBP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on AVBP

Strangles on AVBP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AVBP chain.

AVBP thesis for this strangle

The market-implied 1-standard-deviation range for AVBP extends from approximately $18.42 on the downside to $37.70 on the upside. A AVBP long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current AVBP IV rank near 22.85% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AVBP at 119.80%. As a Healthcare name, AVBP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AVBP-specific events.

AVBP strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AVBP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AVBP alongside the broader basket even when AVBP-specific fundamentals are unchanged. Always rebuild the position from current AVBP chain quotes before placing a trade.

Frequently asked questions

What is a strangle on AVBP?: A strangle on AVBP is the strangle strategy applied to AVBP (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With AVBP stock trading near $28.06, the strikes shown on this page are snapped to the nearest listed AVBP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are AVBP strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the AVBP strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 119.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a AVBP strangle?: The breakeven for the AVBP strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current AVBP market-implied 1-standard-deviation expected move is approximately 34.35%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on AVBP?: Strangles on AVBP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AVBP chain.
How does current AVBP implied volatility affect this strangle?: AVBP ATM IV is at 119.80% with IV rank near 22.85%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.